Jagannath, S., Lee, H. C., Richter, J. R., Zonder, J. A., Hoffman, J. E., Zhou, Z., Horton, V. G., Fillbrunn, M., Wang, H., Mattera, M., Inocencio, T. J., Xu, Y., Harnett, J., Roccia, T., Kroog, G. S., Rodriguez-Lorenc, K., Knorr, K., Ma, Q., Bumma, N. (2025). Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7531